Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture, and Estimated Bone Strength

The cathepsin K inhibitor odanacatib (ODN), currently in phase 3 development for postmenopausal osteoporosis, has a novel mechanism of action that reduces bone resorption while maintaining bone formation. In phase 2 studies, odanacatib increased areal bone mineral density (aBMD) at the lumbar spine and total hip progressively over 5 years. To determine the effects of ODN on cortical and trabecular bone and estimate changes in bone strength, we conducted a randomized, double‐blind, placebo‐controlled trial, using both quantitative computed tomography (QCT) and high‐resolution peripheral (HR‐p)QCT. In previously published results, odanacatib was superior to placebo with respect to increases in trabecular volumetric BMD (vBMD) and estimated compressive strength at the spine, and integral and trabecular vBMD and estimated strength at the hip. Here, we report the results of HR‐pQCT assessment. A total of 214 postmenopausal women (mean age 64.0 ± 6.8 years and baseline lumbar spine T‐score –1.81 ± 0.83) were randomized to oral ODN 50 mg or placebo, weekly for 2 years. With ODN, significant increases from baseline in total vBMD occurred at the distal radius and tibia. Treatment differences from placebo were also significant (3.84% and 2.63% for radius and tibia, respectively). At both sites, significant differences from placebo were also found in trabecular vBMD, cortical vBMD, cortical thickness, cortical area, and strength (failure load) estimated using finite element analysis of HR‐pQCT scans (treatment differences at radius and tibia = 2.64% and 2.66%). At the distal radius, odanacatib significantly improved trabecular thickness and bone volume/total volume (BV/TV) versus placebo. At a more proximal radial site, odanacatib attenuated the increase in cortical porosity found with placebo (treatment difference = –7.7%, p = 0.066). At the distal tibia, odanacatib significantly improved trabecular number, separation, and BV/TV versus placebo. Safety and tolerability were similar between treatment groups. In conclusion, odanacatib increased cortical and trabecular density, cortical thickness, aspects of trabecular microarchitecture, and estimated strength at the distal radius and distal tibia compared with placebo. © 2014 American Society for Bone and Mineral Research

[1]  S. Khosla,et al.  Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. , 2013, The Journal of clinical endocrinology and metabolism.

[2]  L. Duong,et al.  Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Steven K Boyd,et al.  Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. , 2008, Bone.

[4]  I. Reid Anti-resorptive therapies for osteoporosis. , 2008, Seminars in cell & developmental biology.

[5]  Donald S. Williams,et al.  High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. , 2013, Bone.

[6]  Sharmila Majumdar,et al.  The effect of voxel size on high-resolution peripheral computed tomography measurements of trabecular and cortical bone microstructure. , 2012, Medical physics.

[7]  Bert Van Rietbergen,et al.  Finite Element Analysis Based on In Vivo HR‐pQCT Images of the Distal Radius Is Associated With Wrist Fracture in Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  Peter Varga,et al.  HR-pQCT based FE analysis of the most distal radius section provides an improved prediction of Colles' fracture load in vitro. , 2010, Bone.

[9]  Ralph Müller,et al.  Contribution of In Vivo Structural Measurements and Load/Strength Ratios to the Determination of Forearm Fracture Risk in Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  E. Lewiecki Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. , 2009, IDrugs : the investigational drugs journal.

[11]  B. Dardzinski,et al.  Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. , 2013, The Journal of clinical endocrinology and metabolism.

[12]  P. Delmas,et al.  Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia—a randomized placebo-controlled trial , 2012, Osteoporosis International.

[13]  Bert Van Rietbergen,et al.  Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. , 2010, Bone.

[14]  J. Eisman,et al.  Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  L. Duong,et al.  Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  Steven K. Boyd,et al.  High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group , 2013, Current Osteoporosis Reports.

[17]  Sharmila Majumdar,et al.  Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. , 2010, Bone.

[18]  Donald S. Williams,et al.  Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. , 2012, Bone.

[19]  S. Epstein Is cortical bone hip? What determines cortical bone properties? , 2007, Bone.

[20]  N. Binkley,et al.  Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  R. Rizzoli,et al.  Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  R. G. Richards,et al.  Prediction of bone strength at the distal tibia by HR-pQCT and DXA. , 2012, Bone.

[23]  F. Eckstein,et al.  Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images. , 2002, Bone.

[24]  C. Cooper,et al.  Osteoporosis: trends in epidemiology, pathogenesis and treatment , 2006 .

[25]  Luc Duong,et al.  The osteoclast, bone remodelling and treatment of metabolic bone disease , 2012, European journal of clinical investigation.

[26]  Thomas M Link,et al.  Advances in osteoporosis imaging. , 2009, European journal of radiology.

[27]  Lewiecki Em Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. , 2009 .

[28]  P. Delmas,et al.  Finite element analysis performed on radius and tibia HR‐pQCT images and fragility fractures at all sites in men , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Sandra Schorlemmer,et al.  The role of cortical bone and its microstructure in bone strength. , 2006, Age and ageing.

[30]  Sharmila Majumdar,et al.  A Longitudinal HR-pQCT Study of Alendronate Treatment in Postmenopausal Women With Low Bone Density: Relations Among Density, Cortical and Trabecular Microarchitecture, Biomechanics, and Bone Turnover , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  Sharmila Majumdar,et al.  Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  H. Genant,et al.  Short-term in vivo precision of BMD and parameters of trabecular architecture at the distal forearm and tibia , 2012, Osteoporosis International.